Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) for treatment of non-small cell lung cancer (NSCLC) have been rapidly evolving. ICIs are likely to be more effective but also lead to escalating healthcare costs.

Objectives

The aim of this study was to evaluate the cost effectiveness of immune checkpoint inhibitors (ICIs) for treatment of non-small cell lung cancer (NSCLC).

Methods

We searched the PubMed, Web of Science, and Cochrane Library for studies comparing the cost effectiveness of ICIs for NSCLC. Potential studies identified were independently checked for eligibility by two authors, with disagreement resolved by a third reviewer. Quality of the included studies was evaluated using Consolidated Health Economic Evaluation Reporting Standards checklists.

Results<

SUBMITTER: Ding H 

PROVIDER: S-EPMC7467260 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature